Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mitsumori, K.
Right arrow Articles by Hirose, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitsumori, K.
Right arrow Articles by Hirose, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 58, 43-49 (2000)
Copyright © 2000 by the Society of Toxicology


Carcinogenicity

Modifying Effects of Ethinylestradiol but Not Methoxychlor on N-Ethyl-N-nitrosourea-Induced Uterine Carcinogenesis in Heterozygous p53-Deficient CBA Mice

Kunitoshi Mitsumori*,1, Takeo Shimo{dagger}, Hiroshi Onodera*, Hisayoshi Takagi*, Kazuo Yasuhara*, Toru Tamura*, Yasuji Aoki{dagger}, Osamu Nagata{dagger} and Masao Hirose*

* Division of Pathology, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; and {dagger} Research Department, Research and Development Division, Hokuriku, Seiyaku Company, Ltd., 37-1-1, Inokuchi, Katsuyama, Fukui 911-8555, Japan

It is unknown whether endocrine-disrupting chemicals (EDCs) with estrogenic activities have any modifying effects on uterine carcinogenesis. In our previous study, we established a uterine-carcinogenesis model that is useful for detecting tumor-modifying effects of EDCs by the administration of N-ethyl-N-nitrosourea (ENU) to female heterozygous p53-deficient CBA mice [p53 (+/–) mice]. To investigate the effects of ethinylestradiol (EE) and methoxychlor (MXC) on development of ENU-induced uterine tumors, female p53 (+/–) mice and their wild-type littermates [p53 (+/+) mice] received an intraperitoneal injection of 120 mg/kg body weight (bw) of ENU, followed, in Group 1, by no further treatment; in Group 2, by a diet containing 1 ppm EE; in Group 3, by a diet containing 5 ppm EE for 4 weeks and 2.5 ppm EE thereafter; and in Group 4, by a diet containing 2000 ppm MXC for 26 weeks. Uterine proliferative lesions that were induced were composed of both endometrial-stromal and epithelial-cell types. Endometrial stromal sarcomas were induced in p53 (+/–) mice of Groups 1 to 4, and the incidence (87%) in Group 3 was significantly increased compared to Group 1 (47%). Atypical hyperplasias (clear-cell type) of the endometrial gland in p53 (+/–) mice were seen at incidences of 0, 14, 60, and 0% in Groups 1, 2, 3, and 4, respectively, while their incidence in p53 (+/+) mice was 0, 7, 53, and 0%, respectively, with a significant difference between Groups 1 and 3 in both cases. One p53 (+/–) mouse in Group 3 also had an adenocarcinoma consisting of clear cells, and the PCNA labeling indices of the clear-cell atypical hyperplasias, and this endometrial adenocarcinoma, were higher than those of glandular hyperplasias. The present study suggests that 2.5 ppm EE, but not MXC, exerts tumor-promoting effects on stromal and epithelial proliferative lesions of the uteri in p53 (+/–) mice initiated with ENU.

Key Words: N-ethyl-N-nitrosourea; ethinylestradiol; methoxychlor; uterine tumorigenesis; and heterozygous p53-deficient mice.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
T. Watanabe, Y. Kashida, M. Ueda, H. Onodera, T. Takizawa, M. Hirose, and K. Mitsumori
Inhibition by Ethinylestradiol of N-Ethyl-N-Nitrosourea-Initiated Uterine Carcinogenesis in Transgenic Mice Carrying a Human Prototype C-Ha-ras Gene (rasH2 Mice)
Toxicol Pathol, August 1, 2003; 31(5): 496 - 505.
[Abstract] [PDF]


Home page
Toxicol PatholHome page
E. Floyd, P. Mann, G. Long, and R. Ochoa
The Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists
Toxicol Pathol, January 1, 2002; 30(1): 147 - 156.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.